Dallas Salazar

Amit Dayal

Ning Jia

- Vivani Medical is focused on developing a **six-month semaglutide implant** (NPM-139) for chronic weight management, utilizing its NanoPortal drug delivery technology to enhance patient adherence and tolerability for GLP-1 receptor agonists.  **[0001266806_2217287_1]** **[0001266806_2217287_3]** 
- The company plans to **initiate clinical development for the semaglutide implant in the first half of next year** (2026), building on preclinical data that demonstrated sustained **20% weight loss over a seven-month period** from a single implant.  **[0001266806_2217287_3]** **[0001266806_2217287_6]** 
- Vivani Medical positions its implant as the **only GLP-1 implant actively in development for obesity**, aiming to offer convenient once or twice-yearly dosing to address significant unmet needs in the market.  **[0001266806_2217287_7]**

Vivani Medical Outlines Plans for Semaglutide Implant Clinical Development

- Vivani Medical, Inc. announced the pricing of a **registered direct offering** of **6,000,000 shares** of common stock at **$1.62 per share**.  **[1266806_0001753926-25-001655_ex991_4.htm:0]** 
- A concurrent **private placement** of **3,703,703 shares** of common stock at the same price was made to Gregg Williams, the Chairman of the board.  **[1266806_0001753926-25-001655_ex991_4.htm:0]** 
- The combined offerings are expected to generate **gross proceeds of approximately $15.7 million**.  **[1266806_0001753926-25-001655_ex991_4.htm:0]** 
- The company intends to use the net proceeds to fund **ongoing research and clinical development** of product candidates, as well as for working capital and general corporate purposes.  **[1266806_0001753926-25-001655_ex991_4.htm:0]** 
- The offerings are anticipated to close on or about **October 28, 2025**.  **[1266806_0001753926-25-001655_ex991_4.htm:0]**

Vivani Medical Prices Common Stock Offering

- Vivani Medical Inc. (VANI) is developing **subdermal biopharmaceutical implants** using its proprietary NanoPortal platform to address medication non-adherence in chronic diseases, with an initial focus on the GLP-1 space for obesity and diabetes.  **[1266806_2157827_1]** **[1266806_2157827_3]** 
- The company's lead program, a **semaglutide implant (NPM 139)**, demonstrated **approximately 20% weight loss over a seven-month period** in preclinical studies.  **[1266806_2157827_3]** **[1266806_2157827_6]** 
- Following a successful first-in-human study for its exenatide implant technology, Vivani Medical anticipates initiating clinical development for the semaglutide implant in the **first half of next year**.  **[1266806_2157827_3]** **[1266806_2157827_6]** 
- Vivani Medical announced a spin-off of its subsidiary, Cortigent, with shareholders holding common stock as of **October 8** eligible to receive a dividend of Cortigent shares.  **[1266806_2157827_7]**

Vivani Medical Details Progress on GLP-1 Implant Programs and Cortigent Spin-off

- Vivani Medical, Inc. (VANI) has set **October 8, 2025**, as the **record date** for the spin-off of its wholly-owned subsidiary, Cortigent, Inc..  **[1266806_0001753926-25-001510_vani-20250917.htm:1]** **[1266806_0001753926-25-001510_ex991_1.htm:1]** 
- Vivani stockholders holding common stock as of the record date will receive common stock in Cortigent.  **[1266806_0001753926-25-001510_vani-20250917.htm:1]** **[1266806_0001753926-25-001510_ex991_1.htm:1]**  Cortigent, which develops brain implant devices with neuromodulation technology, is expected to trade on the Nasdaq Stock Market under the ticker symbol **"CRGT"**.  **[1266806_0001753926-25-001510_ex991_1.htm:1]** 
- Following the spin-off, Vivani Medical will sharpen its focus on developing miniature, ultra long-acting GLP-1 implants for weight loss management and type 2 diabetes.  **[1266806_0001753926-25-001510_ex991_1.htm:1]** **[1266806_0001753926-25-001510_ex991_1.htm:2]**  The spin-off is estimated to be complete by **late-2025**.  **[1266806_0001753926-25-001510_ex991_1.htm:2]**

Vivani Medical (VANI)